news
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
List view / Grid view
Venous thromboembolism (VTE)
news
Oral milvexian reduces risk of postoperative venous thromboembolism
Milvexian showed a 12 percent rate of postoperative venous thromboembolism compared to the benchmark rate of 30 percent in a Phase II study.
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, September 2021
The EMA’s drug safety committee (PRAC) assessed risks of thrombocytopenia and venous thromboembolism with the Janssen COVID-19 Vaccine.
news
Vaxzevria has similar safety profile to mRNA COVID-19 vaccines, finds study
New studies show rates of blood clots were similar following vaccination with Vaxzevria and Comirnaty®, plus rates of rare blood clots are lower after the second Vaxzevria dose.
news
XARELTO® approved to help prevent blood clots
The FDA has approved XARELTO® (rivaroxaban) to help prevent blood clots in acutely ill medical patients.
news
New anti-clotting drugs linked to lower risk of serious bleeding
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
news
FDA approves new dosing for Xarelto to reduce the risk of VTE
The FDA has approved the 10 mg once-daily dose of Xarelto, for reducing the continued risk of recurrent venous thromboembolism...
news
DOACs used as a alternative to warfarin to treat venous thromboembolism
A study has found that a new group of drugs used to treat patients with serious blood clots are not associated with a higher risk of major bleeding compared with warfarin...
news
Atrial fibrillation market will peak at $11.8 billion in 2022
2 August 2016 | By GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...
news
Venous thromboembolism (VTE) therapeutics market set to hit $3.7 billion by 2025
1 August 2016 | By GlobalData
Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report...
news
Servier Canada to market edoxaban in Canada
27 June 2016 | By Victoria White, Digital Content Producer
Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting...
news
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
news
Daiichi Sankyo helps raise awareness of VTE and AF
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
news
NICE recommends edoxaban for deep vein thrombosis
26 August 2015 | By Victoria White
NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS...
news
Real world ETNA registries of new once-daily edoxaban start in Europe
24 August 2015 | By Victoria White
ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings...
